Cerebrovascular pathology during the progression of experimental Alzheimer's disease

Neurobiology of Disease

Volumn 88, Issue , 2016, Pages 107-117

  Giannoni, Patrizia ^a,b   Arango Lievano, Margarita ^a,b   Neves, Ines Das ^a,b   Rousset, Marie Claude ^a,b   Baranger, Kévin ^c   Rivera, Santiago ^c   Jeanneteau, Freddy ^a,b   Claeysen, Sylvie ^a,b   Marchi, Nicola ^a,b  

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b UNIV MONTPELLIER   (France)

^c Mediterranée University   (France)

Author keywords

5xFAD; Alzheimer; CAA; Microvascular inflammation

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CD31 ANTIGEN; COLLAGEN TYPE 4; FLUORESCEIN ISOTHIOCYANATE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PRESENILIN; ACTIN BINDING PROTEIN; AIF1 PROTEIN, MOUSE; CALCIUM BINDING PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

5XFAD MOUSE; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BASEMENT MEMBRANE; BRAIN BLOOD VESSEL; BRAIN CORTEX; BRAIN TISSUE; CEREBROVASCULAR DISEASE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DISEASE COURSE; ENDOTHELIUM CELL; EXPERIMENTAL DISEASE; FRONTOPARIETAL CORTEX; GENE MUTATION; IN VIVO STUDY; LEPTOMENINX; MICROANGIOGRAPHY; MICROGLIA; MOUSE; MOUSE MODEL; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR AMYLOIDOSIS; WILD TYPE MOUSE; AGE; ANIMAL; BLOOD VESSEL; BRAIN CIRCULATION; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIGENS, CD31; BLOOD VESSELS; CALCIUM-BINDING PROTEINS; CEREBROVASCULAR CIRCULATION; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MICE; MICE, TRANSGENIC; MICROFILAMENT PROTEINS; MUTATION; PERICYTES; PLAQUE, AMYLOID; PRESENILIN-1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 84954483931     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.01.001     Document Type: Article

References (63)

1. Abbott N.J., Patabendige A.A., Dolman D.E., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010, 37:13-25.
2. Abbott N.J., Ronnback L., Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 2006, 7:41-53.
3. Armulik A., Genove G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 2011, 21:193-215.
4. Armulik A., Genove G., Mae M., Nisancioglu M.H., Wallgard E., Niaudet C., He L., Norlin J., Lindblom P., Strittmatter K., Johansson B.R., Betsholtz C. Pericytes regulate the blood-brain barrier. Nature 2010, 468:557-561.
5. Attems J. Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. Acta Neuropathol. 2005, 110:345-359.
6. Bell R.D., Winkler E.A., Sagare A.P., Singh I., LaRue B., Deane R., Zlokovic B.V. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010, 68:409-427.
7. Bien-Ly N., Boswell C.A., Jeet S., Beach T.G., Hoyte K., Luk W., Shihadeh V., Ulufatu S., Foreman O., Lu Y., DeVoss J., van der Brug M., Watts R.J. Lack of widespread BBB disruption in Alzheimer's disease models: focus on therapeutic antibodies. Neuron 2015, 88:289-297.
8. Bilkei-Gorzo A. Genetic mouse models of brain ageing and Alzheimer's disease. Pharmacol. Ther. 2014, 142:244-257.
9. Breitner J.C., Baker L.D., Montine T.J., Meinert C.L., Lyketsos C.G., Ashe K.H., Brandt J., Craft S., Evans D.E., Green R.C., Ismail M.S., Martin B.K., Mullan M.J., Sabbagh M., Tariot P.N., Group AR Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 2011, 7:402-411.
10. Breteler M.M. Vascular involvement in cognitive decline and dementia. Epidemiologic evidence from the Rotterdam Study and the Rotterdam Scan Study. Ann. N. Y. Acad. Sci. 2000, 903:457-465.
11. Breteler M.M. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol. Aging 2000, 21:153-160.
12. Carare R.O., Bernardes-Silva M., Newman T.A., Page A.M., Nicoll J.A., Perry V.H., Weller R.O. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol. 2008, 34:131-144.
13. Carare R.O., Hawkes C.A., Jeffrey M., Kalaria R.N., Weller R.O. Review: cerebral amyloid angiopathy, prion angiopathy, CADASIL and the spectrum of protein elimination failure angiopathies (PEFA) in neurodegenerative disease with a focus on therapy. Neuropathol. Appl. Neurobiol. 2013, 39:593-611.
14. Carare R.O., Hawkes C.A., Weller R.O. Afferent and efferent immunological pathways of the brain. Anatomy, function and failure. Brain Behav. Immun. 2014, 36:9-14.
15. Cifuentes D., Poittevin M., Dere E., Broqueres-You D., Bonnin P., Benessiano J., Pocard M., Mariani J., Kubis N., Merkulova-Rainon T., Levy B.I. Hypertension accelerates the progression of Alzheimer-like pathology in a mouse model of the disease. Hypertension 2015, 65:218-224.
16. Deane R., Bell R.D., Sagare A., Zlokovic B.V. Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 2009, 8:16-30.
17. Do T.M., Alata W., Dodacki A., Traversy M.T., Chacun H., Pradier L., Scherrmann J.M., Farinotti R., Calon F., Bourasset F. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease. Neuropharmacology 2014, 81:311-317.
18. Dorr A., Sahota B., Chinta L.V., Brown M.E., Lai A.Y., Ma K., Hawkes C.A., McLaurin J., Stefanovic B. Amyloid-beta-dependent compromise of microvascular structure and function in a model of Alzheimer's disease. Brain J. Neurol. 2012, 135:3039-3050.
19. Elder G.A., Gama Sosa M.A., De Gasperi R. Transgenic mouse models of Alzheimer's disease. Mt. Sinai J. Med. N. Y. 2010, 77:69-81.
20. Fernandez-Klett F., Potas J.R., Hilpert D., Blazej K., Radke J., Huck J., Engel O., Stenzel W., Genove G., Priller J. Early loss of pericytes and perivascular stromal cell-induced scar formation after stroke. J. Cereb. Blood Flow Metab. 2013, 33:428-439.
21. Giannoni P., Gaven F., de Bundel D., Baranger K., Marchetti-Gauthier E., Roman F.S., Valjent E., Marin P., Bockaert J., Rivera S., Claeysen S. Early administration of RS 67333, a specific 5-HT4 receptor agonist, prevents amyloidogenesis and behavioral deficits in the 5XFAD mouse model of Alzheimer's disease. Front. Aging Neurosci. 2013, 5:96.
22. Gupta P.P., Pandey R.D., Jha D., Shrivastav V., Kumar S. Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: a meta-analysis of randomized clinical trials. Am. J. Alzheimers Dis. Other Demen. 2015, 30:178-182.
23. Hawkes C.A., McLaurin J. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:1261-1266.
24. Hayden K.M., Zandi P.P., Lyketsos C.G., Khachaturian A.S., Bastian L.A., Charoonruk G., Tschanz J.T., Norton M.C., Pieper C.F., Munger R.G., Breitner J.C., Welsh-Bohmer K.A., Cache County I. Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study. Alzheimer Dis. Assoc. Disord. 2006, 20:93-100.
25. Heppner F.L., Ransohoff R.M., Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat. Rev. Neurosci. 2015, 16:358-372.
26. Herzig M.C., Winkler D.T., Burgermeister P., Pfeifer M., Kohler E., Schmidt S.D., Danner S., Abramowski D., Sturchler-Pierrat C., Burki K., van Duinen S.G., Maat-Schieman M.L., Staufenbiel M., Mathews P.M., Jucker M. Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 2004, 7:954-960.
27. Hofman A., Ott A., Breteler M.M., Bots M.L., Slooter A.J., van Harskamp F., van Duijn C.N., Van Broeckhoven C., Grobbee D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997, 349:151-154.
28. Howlett D.R. APP transgenic mice and their application to drug discovery. Histol. Histopathol. 2011, 26:1611-1632.
29. Iliff J.J., Goldman S.A., Nedergaard M. Implications of the discovery of brain lymphatic pathways. Lancet Neurol. 2015, 14:977-979.
30. Iliff J.J., Wang M., Liao Y., Plogg B.A., Peng W., Gundersen G.A., Benveniste H., Vates G.E., Deane R., Goldman S.A., Nagelhus E.A., Nedergaard M. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl. Med. 2012, 4.
31. Janota C.S., Brites D., Lemere C.A., Brito M.A. Glio-vascular changes during ageing in wild-type and Alzheimers disease-like APP/PS1 mice. Brain Res. 2015.
32. Janota C., Lemere C.A., Brito M.A. Dissecting the contribution of vascular alterations and aging to Alzheimer's disease. Mol. Neurobiol. 2015.
33. Jawhar S., Trawicka A., Jenneckens C., Bayer T.A., Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5XFAD mouse model of Alzheimer's disease. Neurobiol. Aging 2012, 33(196):e129-e140.
34. Keable A., Fenna K., Yuen H.M., Johnston D.A., Smyth N.R., Smith C., Salman R.A., Samarasekera N., Nicoll J.A., Attems J., Kalaria R.N., Weller R.O., Carare R.O. Deposition of amyloid beta in the walls of human leptomeningeal arteries in relation to perivascular drainage pathways in cerebral amyloid angiopathy. Biochim. Biophys. Acta 2015.
35. Kester M.I., Goos J.D., Teunissen C.E., Benedictus M.R., Bouwman F.H., Wattjes M.P., Barkhof F., Scheltens P., van der Flier W.M. Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. JAMA Neurol. 2014, 71:855-862.
36. Klohs J., Rudin M., Shimshek D.R., Beckmann N. Imaging of cerebrovascular pathology in animal models of Alzheimer's disease. Front. Aging Neurosci. 2014, 6:32.
37. Klunk W.E., Bacskai B.J., Mathis C.A., Kajdasz S.T., McLellan M.E., Frosch M.P., Debnath M.L., Holt D.P., Wang Y., Hyman B.T. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J. Neuropathol. Exp. Neurol. 2002, 61:797-805.
38. Kook S.Y., Hong H.S., Moon M., Ha C.M., Chang S., Mook-Jung I. Abeta(1)(-)(4)(2)-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca(2)(+)-calcineurin signaling. J. Neurosci. Off. J. Soc. Neurosci. 2012, 32:8845-8854.
39. Kook S.Y., Seok Hong H., Moon M., Mook-Jung I. Disruption of blood-brain barrier in Alzheimer disease pathogenesis. Tissue barriers 2013, 1.
40. Kovari E., Charidimou A., Herrmann F.R., Giannakopoulos P., Bouras C., Gold G. No neuropathological evidence for a direct topographical relation between microbleeds and cerebral amyloid angiopathy. Acta Neuropathol. Commun. 2015, 3:49.
41. Lai A.Y., Dorr A., Thomason L.A., Koletar M.M., Sled J.G., Stefanovic B., McLaurin J. Venular degeneration leads to vascular dysfunction in a transgenic model of Alzheimer's disease. Brain J. Neurol. 2015, 138:1046-1058.
42. Luchsinger J.A., Reitz C., Honig L.S., Tang M.X., Shea S., Mayeux R. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005, 65:545-551.
43. Marchesi V.T. Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J. 2011, 25:5-13.
44. Marques F., Sousa J.C., Sousa N., Palha J.A. Blood-brain-barriers in aging and in Alzheimer's disease. Mol. Neurodegener. 2013, 8:38.
45. Miners J.S., Baig S., Palmer J., Palmer L.E., Kehoe P.G., Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 2008, 18:240-252.
46. Mineur Y.S., McLoughlin D., Crusio W.E., Sluyter F. Genetic mouse models of Alzheimer's disease. Neural Plast. 2005, 12:299-310.
47. Montagne A., Barnes S.R., Sweeney M.D., Halliday M.R., Sagare A.P., Zhao Z., Toga A.W., Jacobs R.E., Liu C.Y., Amezcua L., Harrington M.G., Chui H.C., Law M., Zlokovic B.V. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015, 85:296-302.
48. Montagne A., Pa J., Zlokovic B.V. Vascular plasticity and cognition during normal aging and dementia. JAMA Neurol. 2015, 72:495-496.
49. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. Off. J. Soc. Neurosci. 2006, 26:10129-10140.
50. Park L., Zhou J., Zhou P., Pistick R., El Jamal S., Younkin L., Pierce J., Arreguin A., Anrather J., Younkin S.G., Carlson G.A., McEwen B.S., Iadecola C. Innate immunity receptor CD36 promotes cerebral amyloid angiopathy. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:3089-3094.
51. Sagare A.P., Sweeney M.D., Makshanoff J., Zlokovic B.V. Shedding of soluble platelet-derived growth factor receptor-beta from human brain pericytes. Neurosci. Lett. 2015, 607:97-101.
52. Thal D.R., Griffin W.S., Braak H. Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. J. Cell. Mol. Med. 2008, 12:1848-1862.
53. Trepanier C.H., Milgram N.W. Neuroinflammation in Alzheimer's disease: are NSAIDs and selective COX-2 inhibitors the next line of therapy?. J. Alzheimers Dis. 2010, 21:1089-1099.
54. Ujiie M., Dickstein D.L., Carlow D.A., Jefferies W.A. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 2003, 10:463-470.
55. Verclytte S., Lopes R., Lenfant P., Rollin A., Semah F., Leclerc X., Pasquier F., Delmaire C. Cerebral hypoperfusion and hypometabolism detected by arterial spin labeling MRI and FDG-PET in early-onset Alzheimer's disease. J. Neuroimaging 2015.
56. Weller R.O., Preston S.D., Subash M., Carare R.O. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res. Ther. 2009, 1:6.
57. Weller R.O., Subash M., Preston S.D., Mazanti I., Carare R.O. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 2008, 18:253-266.
58. Winkler E.A., Bell R.D., Zlokovic B.V. Pericyte-specific expression of PDGF beta receptor in mouse models with normal and deficient PDGF beta receptor signaling. Mol. Neurodegener. 2010, 5:32.
59. Winkler E.A., Bell R.D., Zlokovic B.V. Central nervous system pericytes in health and disease. Nat. Neurosci. 2011, 14:1398-1405.
60. Xu F., Kotarba A.E., Ou-Yang M.H., Fu Z., Davis J., Smith S.O., Van Nostrand W.E. Early-onset formation of parenchymal plaque amyloid abrogates cerebral microvascular amyloid accumulation in transgenic mice. J. Biol. Chem. 2014, 289:17895-17908.
61. Yang G., Pan F., Parkhurst C.N., Grutzendler J., Gan W.B. Thinned-skull cranial window technique for long-term imaging of the cortex in live mice. Nat. Protoc. 2010, 5:201-208.
62. Zenaro E., Pietronigro E., Bianca V.D., Piacentino G., Marongiu L., Budui S., Turano E., Rossi B., Angiari S., Dusi S., Montresor A., Carlucci T., Nani S., Tosadori G., Calciano L., Catalucci D., Berton G., Bonetti B., Constantin G. Neutrophils promote Alzheimer's disease-like pathology and cognitive decline via LFA-1 integrin. Nat. Med. 2015, 21:880-886.
63. Zlokovic B.V., Deane R., Sagare A.P., Bell R.D., Winkler E.A. Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid beta-peptide elimination from the brain. J. Neurochem. 2010, 115:1077-1089.